KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Treasury Shares (2016 - 2025)

Historic Treasury Shares for AbbVie (ABBV) over the last 13 years, with Q3 2025 value amounting to $9.1 billion.

  • AbbVie's Treasury Shares rose 1650.1% to $9.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $9.1 billion, marking a year-over-year increase of 1650.1%. This contributed to the annual value of $8.2 billion for FY2024, which is 2553.19% up from last year.
  • AbbVie's Treasury Shares amounted to $70.8 million in Q3 2025, which was up 91126.7% from $70.8 million recorded in Q2 2025.
  • Over the past 5 years, AbbVie's Treasury Shares peaked at $70.8 million during Q2 2025, and registered a low of $7.0 million during Q1 2021.
  • For the 5-year period, AbbVie's Treasury Shares averaged around $24.3 million, with its median value being $10.0 million (2022).
  • Examining YoY changes over the last 5 years, AbbVie's Treasury Shares showed a top increase of 5434.12% in 2021 and a maximum decrease of 8798.49% in 2021.
  • AbbVie's Treasury Shares (Quarter) stood at $3.1 billion in 2021, then skyrocketed by 46.17% to $4.6 billion in 2022, then soared by 42.21% to $6.5 billion in 2023, then rose by 25.53% to $8.2 billion in 2024, then rose by 11.49% to $9.1 billion in 2025.
  • Its Treasury Shares was $9.1 billion in Q3 2025, compared to $9.1 billion in Q2 2025 and $9.1 billion in Q1 2025.